Novel Discovery ~ Mechanism of Action

Use of EVs Derived from BM-MSCs

Leksum’s novel discovery for the treatment of muscle myopathy that underpins the Muscle Regeneration Platform was supported by more than $30 million of funding primarily in the form of grants from major funding agencies including the European Commission and the National Institutes of Health.

Bone marrow-derived mesenchymal stromal cells (BM-MSCs) promote activation of endogenous repair pathways and reprogramming of immune cells, leading to modulation of inflammatory and remodeling processes.¹

BM-MSCs generate biologically active extracellular vesicles (EVs).

Discovery: The systemic administration of multiple doses of EVs derived from BM-MSCs offers a novel approach to combatting the lung injury associated with MV ².

Usage of EVs is preferred to that of stem cells for several reasons including safety, efficacy, lower cost, and they are easier to store³.

Histology sample Red marrow smear under light microscopy

1/ The first MSC therapy was approved by the U.S. FDA in December 2024 (see here), thus providing precedence for Leksum’s novel therapy of employing EVs derived from BM-MSCs.
2/ Leksum’s novel discovery of the use of EVs to treat multiple muscle myopathies and other related conditions are protected by patent filings.
3/ For more information regarding the manufacturing of EVs please see here.

Novel Discovery ~ Mechanism of Action

Use of EVs Derived from BM-MSCs

Discovery: The systemic administration of multiple doses of EVs derived from BM-MSCs offers a novel approach to combatting the lung injury associated with MV 2.

Discovery: The systemic administration of multiple doses of EVs derived from BM-MSCs offers a novel approach to combatting the lung injury associated with MV ².